Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy.

Monoclonal antibodies against an estrogen-regulated Mr 24,000 cytosol protein (p24) were used for immunocytochemical localization of p24 in formalin-fixed paraffin-embedded specimens from the primary tumor in 103 patients who received endocrine therapy for advanced breast cancer. Sixty-one per cent of the tumors showed p24-positive staining, and this correlated well with the presence of estrogen receptor (ER) (P = 0.00017, chi-square test). Response to endocrine therapy was obtained in 43% of the patients. A statistically significant association between p24 status and response could not be established, while response and ER status were highly correlated (P = 0.0000029, chi-square = 21.6). Discrimination between ER-positive responders and ER-positive non-responders was not possible using p24 staining.
AuthorsJ Andersen, H Skovbon, H S Poulsen
JournalEuropean journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 25 Issue 4 Pg. 641-3 (Apr 1989) ISSN: 0277-5379 [Print] ENGLAND
PMID2714341 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • HSP27 Heat-Shock Proteins
  • HSPB1 protein, human
  • Heat-Shock Proteins
  • Neoplasm Proteins
  • Receptors, Estrogen
  • estrogen regulated protein
  • Tamoxifen
  • Breast Neoplasms (analysis, therapy)
  • Female
  • HSP27 Heat-Shock Proteins
  • Heat-Shock Proteins
  • Humans
  • Neoplasm Proteins (analysis)
  • Ovariectomy
  • Receptors, Estrogen (analysis)
  • Tamoxifen (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: